DeepMed Research

Ticagrelor

Generic Name: Ticagrelor

Brand Names: Brilinta, Brilique

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈F_₂N_₆O_₄S

CAS Number: 274693-27-5

Unique Ingredient Identifier: GLH0314RVC

Background: Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication: Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions: Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)

Clinical Trials

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

Not Applicable

Not yet recruiting

Conditions: Intracranial Atherosclerosis

Interventions: Genetic: Point-of-Care CYP2C19 Testing
Drug: ticagrelor + aspirin
Drug: clopidogrel + aspirin

First Posted Date: 2024-12-03

Last Posted Date: 2025-05-18

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 100

Registration Number: NCT06714526

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
Dr. Mark I. Boulos - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Phase 4

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Ticagrelor 90 mg
Drug: Prasugrel 10 mg

First Posted Date: 2024-11-15

Last Posted Date: 2025-01-27

Lead Sponsor: University of Florida

Target Recruit Count: 48

Registration Number: NCT06691191

Locations: 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States

A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects

Phase 1

Active, not recruiting

Conditions: Insomnia

Interventions: Drug: YZJ-1139 tablets
Drug: Ticagrelor Tablets

First Posted Date: 2024-11-04

Last Posted Date: 2024-11-04

Lead Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT06671470

Locations: 🇨🇳
Shulan (Hangzhou) Hospital, Huangzhou, China

TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk

Phase 4

Completed

Conditions: STEMI - ST Elevation Myocardial Infarction
Stent Thrombosis
Antiplatelet Agents

Interventions: Drug: Ticagrelor

First Posted Date: 2024-10-31

Last Posted Date: 2024-10-31

Lead Sponsor: National Institute of Cardiovascular Diseases, Pakistan

Target Recruit Count: 1727

Registration Number: NCT06667349

Locations: 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan

Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke

Phase 2

Recruiting

Conditions: Ischemic Stroke
Transient Ischemic Attack

Interventions: Drug: Ticagrelor 60 + Aspirin
Drug: Ticagrelor 90 + aspirin

First Posted Date: 2024-10-22

Last Posted Date: 2025-04-27

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT06653348

Locations: 🇮🇷
Mazandaran province, Sari,Iran, Sari, Mazandaran, Iran, Islamic Republic of

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Cilostazol 100 MG
Drug: Aspirin 75mg

First Posted Date: 2024-09-19

Last Posted Date: 2025-01-13

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06591377

Locations: 🇪🇬
El-sahel teaching hospital, Cairo, Egypt
🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Clopidogrel

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06591338

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Clopidogrel

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06591312

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Cilostazol 100 MG

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06591390

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Phase 1

Completed

Conditions: Acute Coronary Syndrome
Ischemic Stroke

Interventions: Drug: Tiprogrel
Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2024-09-05

Last Posted Date: 2025-01-06

Lead Sponsor: Tianjin Institute of Pharmaceutical Research Co., Ltd

Target Recruit Count: 14

Registration Number: NCT06584812

Locations: 🇨🇳
Beijing Tiantan Hosptial, Capital Medical University, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy